Pegvaliase

CHEMBL4297802 Phase 4 已批准 Enzyme

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

318.4 g/mol

LogP

-2.3

Phase

4

This enzyme therapy treats phenylketonuria (PKU) by providing a functional enzyme to lower phenylalanine levels.

分子量

318.4100 g/mol

LogP

-2.30

TPSA

111.00 Å²

Lipinski 五规则

符合

Pharmacokinetics (PK)

Pharmacodynamics (PD)

SMILES

COCCOCCCCCC(=O)NCCCC[C@@H](C(=O)O)N

InChI

InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1

Molecular Formula

C15H30N2O5

HBD / HBA

3 / 6

可旋转键数

15

重原子数

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This enzyme therapy treats phenylketonuria (PKU) by providing a functional enzyme to lower phenylalanine levels.

Yes, Pegvaliase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297802. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 86278362. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

正在寻找患者友好型信息？

Pegvaliase 在 PillFYI 上

快速数据

分子式: C15H30N2O5
同义词: 1

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.